Vincerx Pharma, Inc. (VINC)
Largest Insider Buys in Sector
VINC Stock Price History Chart
VINC Stock Performance
About Vincerx Pharma, Inc.
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. …
Insider Activity of Vincerx Pharma, Inc.
Over the last 12 months, insiders at Vincerx Pharma, Inc. have bought $0 and sold $0 worth of Vincerx Pharma, Inc. stock.
On average, over the past 5 years, insiders at Vincerx Pharma, Inc. have bought $355,970 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,500 shares for transaction amount of $9,968 was made by Seelenberger Alexander A. (See Remarks) on 2023‑08‑11.
List of Insider Buy and Sell Transactions, Vincerx Pharma, Inc.
| 2023-08-11 | See Remarks | 10,500 0.0503% | $0.95 | $9,968 | -5.07% | |||
| 2023-08-10 | See Remarks | 5,000 0.0241% | $0.95 | $4,750 | -7.00% | |||
| 2023-08-10 | See Remarks | 5,400 0.0263% | $0.96 | $5,167 | -7.00% | |||
| 2023-08-10 | See Remarks | 3,440 0.0163% | $0.93 | $3,199 | -7.00% | |||
| 2023-08-09 | See Remarks | 16,900 0.0827% | $0.95 | $15,994 | -5.38% | |||
| 2023-08-09 | See Remarks | 13,036 0.0607% | $0.90 | $11,735 | -5.38% | |||
| 2022-12-14 | Chief Executive Officer | 35,280 0.1661% | $0.87 | $30,538 | +15.52% | |||
| 2022-12-14 | See Remarks | 28,738 0.1383% | $0.88 | $25,427 | +15.52% | |||
| 2022-12-14 | See Remarks | 7,000 0.0316% | $0.83 | $5,810 | +15.52% | |||
| 2022-08-24 | 18,400 0.0871% | $1.65 | $30,299 | -33.33% | ||||
| 2022-06-27 | See Remarks | 40,000 0.193% | $1.41 | $56,312 | -12.95% | |||
| 2022-06-23 | Chief Executive Officer | 24,200 0.1121% | $1.41 | $34,137 | -16.55% | |||
| 2022-06-09 | 15,000 0.0725% | $1.91 | $28,625 | -35.64% | ||||
| 2021-12-23 | Chief Business Officer | 3,000 0.0144% | $10.00 | $30,000 | -84.35% | |||
| 2021-12-22 | Chief Executive Officer | 6,450 0.0301% | $10.02 | $64,650 | -84.71% | |||
| 2021-12-22 | Chief Financial Officer | 2,417 0.0116% | $10.34 | $24,988 | -84.71% | |||
| 2021-12-22 | director | 2,402 0.0117% | $10.48 | $25,173 | -84.71% | |||
| 2021-12-22 | See Remarks | 1,000 0.0048% | $10.23 | $10,230 | -84.71% | |||
| 2021-08-04 | See Remarks | 1,000 0.0058% | $11.96 | $11,960 | -41.48% | |||
| 2021-06-30 | Chief Business Officer | 500 0.0028% | $12.66 | $6,330 | -24.44% |
Insider Historical Profitability
| Hwang Sooin | Chief Business Officer | 390491 1.1604% | $0.19 | 2 | 0 | <0.0001% |
| THOMAS TOM C | See Remarks | 219935 0.6536% | $0.19 | 4 | 0 | <0.0001% |
| Hamdy Ahmed MD | See Remarks | 96060 0.2855% | $0.19 | 6 | 0 | <0.0001% |
| Izumi Raquel E. | See Remarks | 85214 0.2532% | $0.19 | 5 | 0 | <0.0001% |
| Seelenberger Alexander A. | See Remarks | 30280 0.09% | $0.19 | 3 | 0 | <0.0001% |
Institutional Investor Ownership
| Sage Rhino Capital LLC | $8.62M | 5.74 | 1.7M | 0% | +$0 | 2.14 | |
| Octagon Capital Advisors LP | $5.06M | 3.37 | 1M | New | +$5.06M | 0.03 | |
| Point72 Asset Management | $4.83M | 3.22 | 954,827 | +176.9% | +$3.09M | 0.01 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $4.51M | 3.01 | 891,719 | 0% | +$0 | 0.12 | |
| Bank of America | $3.55M | 2.36 | 701,423 | -35.23% | -$1.93M | <0.0001 |